Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Am J Obstet Gynecol. 2005 Nov;193(5):1630-9.

Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial.

Author information

  • 1Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112-5550, USA. saundra.buys@hsc.utah.edu

Erratum in

  • Am J Obstet Gynecol. 2005 Dec;193(6):2183-4.

Abstract

OBJECTIVE:

Ovarian cancer screening with transvaginal ultrasound (TVU) and CA-125 was evaluated in the Prostate, Lung, Colorectal and Ovarian (PLCO) Trial.

STUDY DESIGN:

This was a randomized controlled trial of screening versus usual care. Baseline screening results are reported.

RESULTS:

Of 39,115 women randomized to receive screening, 28,816 received at least 1 test. Abnormal TVU was found in 1338 (4.7%), and abnormal CA-125 in 402 (1.4%). Twenty-nine neoplasms were identified (26 ovarian, 2 fallopian, and 1 primary peritoneal neoplasm). Nine were tumors of low malignant potential and 20 were invasive. The positive predictive value for invasive cancer was 3.7% for an abnormal CA-125, 1.0% for an abnormal TVU, and 23.5% if both tests were abnormal.

CONCLUSION:

The effect of screening on ovarian cancer mortality in the PLCO cohort has yet to be evaluated and will require longer follow-up. Screening identified both early- and late-stage neoplasms, and the predictive value of both tests was relatively low.

PMID:
16260202
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk